Latest Recruitment News

CLINUVEL Pharmaceuticals has received final scientific advice from the European Medicines Agency on the design of its pivotal Phase III trial for SCENESSE in vitiligo, endorsing a comprehensive evidence approach and prioritising patients with darker skin tones.

PLS Group delivered a record 232.4kt spodumene concentrate production in March 2026, lifted revenue 52% to A$567 million on soaring lithium prices, and strengthened its balance sheet with a US$600 million senior notes issuance.

Cambium Bio has secured FDA confirmation that a single pivotal Phase 3 trial plus confirmatory evidence will suffice for Biologics License Application submission for Elate Ocular, significantly reducing development expenses and accelerating the pathway to market.

Cavalier Resources has secured a $4 million placement at an 11.95% discount to the 15-day VWAP, funding critical pre-production activities at its Crawford Gold Project. This capital injection complements ongoing negotiations for a US$13 million gold prepayment and a A$5 million loan, advancing the project toward production.

Racura Oncology has detailed how its lead drug candidate, (E,E)-bisantrene, silences the cancer-driving MYC gene by stabilising G-quadruplex DNA structures, providing critical preclinical validation ahead of ongoing clinical trials.

Metal Powder Works nearly doubled its powder revenue in Q1 2026 while maintaining strong margins, secured its first NATO defence contract under the UK Ministry of Defence’s Project TAMPA, and advanced its Next Gen powder production system on schedule.

Kaiser Reef reports promising drilling results and key infrastructure upgrades at its Maldon Gold Project, setting the stage for expanded exploration and production in Victoria’s historic gold district.

Firebrick Pharma secured regulatory approval for Nasodine Nasal Spray in Indonesia and launched Nasodine Throat Spray in Singapore and Fiji, while raising $1.5 million to fuel growth. The company aims to quadruple its product and market footprint within three years.

Invion Limited is broadening its non-melanoma skin cancer trial to include basal cell carcinoma patients following encouraging safety and efficacy data from squamous cell carcinoma cohorts, targeting the largest skin cancer segment.

Hiremii Limited has delivered its most profitable quarter yet, reporting record revenue and gross profit alongside its first positive adjusted EBITDA. The company also secured its first recurring SaaS contracts, marking a milestone in its shift towards a technology-driven workforce intelligence model.

Emyria has unveiled the Empax Global Partnership Program, a high-margin clinical delivery platform targeting international drug sponsors amid growing demand for psychedelic-assisted mental health treatments.

29Metals Limited (ASX:29M) swung to a $24 million net profit in 2025, powered by steady copper output at Golden Grove despite seismic disruptions, cost efficiencies, and key progress on growth projects including Gossan Valley and Capricorn Copper restart.